Last €26.03 EUR
Change Today +1.29 / 5.20%
Volume 715.4K
SAZ On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 3:36 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (SAZ) Snapshot

Open
€24.89
Previous Close
€24.74
Day High
€26.10
Day Low
€24.85
52 Week High
01/22/14 - €39.01
52 Week Low
12/17/14 - €24.10
Market Cap
1.6B
Average Volume 10 Days
542.5K
EPS TTM
€2.17
Shares Outstanding
60.6M
EX-Date
06/5/14
P/E TM
12.0x
Dividend
€0.66
Dividend Yield
2.54%
Current Stock Chart for STADA ARZNEIMITTEL AG (SAZ)

Related News

No related news articles were found.

stada arzneimittel ag (SAZ) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel ag (SAZ) Details

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates primarily in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s primarily products include Phospholipide, a liver medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Enalapril, an ACE inhibitor; and Omeprazole, a stomach medicine. The Branded Products segment offers non-prescription products, such as Grippostad and Ladival. This segment’s products also comprise Apo-Go, a Parkinson medicine; Snup, a nasal preparation; Zaldiar, a pain medicine; Chondroxid for the treatment of degenerative joint diseases; and Ladival, a sun cream. The company has license and collaboration agreements with Gedeon Richter Plc for the development and marketing of biosimilar products for two monoclonal antibodies rituximab and optionally trastuzumab. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany.

9,825 Employees
Last Reported Date: 03/26/14
Founded in 1895

stada arzneimittel ag (SAZ) Top Compensated Officers

Chairman of the Executive Board and Chief Exe...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.4M
Chief Business Development & Central Services...
Total Annual Compensation: €844.6K
Compensation as of Fiscal Year 2013.

stada arzneimittel ag (SAZ) Key Developments

Stada Reportedly Sells Storage Operations To DHL

Stada-Arzneimittel AG (DB:SAZ) has reportedly sold its storage operations to DHL International GmbH for an undisclosed price.

Stada-Arzneimittel AG Presents at 12th Berenberg European Conference, Dec-03-2014 11:45 AM

Stada-Arzneimittel AG Presents at 12th Berenberg European Conference, Dec-03-2014 11:45 AM. Venue: Pennyhill Park Hotel & Spa, London Road, Bagshot, Surrey GU19 5EU, United Kingdom. Speakers: Helmut Kraft, Chief Financial Officer and Member of Executive Board, Metzger , Vice President IR.

Stada-Arzneimittel Ag Reports Group Earnings Results for the Nine Months of 2014; Provides Earnings Guidance for the Full Year of 2014

Stada-Arzneimittel AG reported group earnings results for the nine months of 2014. For the period, group sales were EUR 1,482.7 million against EUR 1,426.2 million a year ago. Reported EBITDA was EUR 293.6 million against EUR 267.0 million a year ago. Adjusted EBITDA was EUR 316.2 million against EUR 283.5 million a year ago. Reported net income was EUR 99.1 million against EUR 90.2 million a year ago. Adjusted net income was EUR 136.1 million against EUR 100.3 million a year ago. Earnings per share were EUR 1.64 against EUR 1.52 a year ago. Adjusted earnings per share were EUR 2.25 against EUR 1.69 a year ago. This development was positively influenced by earnings in the amount of EUR 15.9 million before and approximately EUR 11 million after taxes resulting from a change in the defined benefit plan for the chairman of the executive board, which had been planned for a long time and implemented in August. The disproportionate increase in net profit can primarily be attributed to a substantial reduction of the effective tax rate as of the first quarter of 2014. This development results from a changed profit allocation in the STADA Group. The company confirms the outlook for financial year 2014. According to this, the company expects slight growth in group sales, adjusted EBITDA and adjusted net income. For reasons of transparency, the adjustments as from 2014 include currency translation effects recorded in the income statement from the fluctuation of the Russian ruble as well as further significant currencies of the market region CIS /Eastern Europe and burdens from additional impairments and other measurement effects due to purchase price allocations as well as significant product acquisitions taking financial year 2013 as basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAZ:GR €26.03 EUR +1.29

SAZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Richter Gedeon Nyrt 3,370 -99.00
Impax Laboratories Inc $30.79 USD +0.86
Oxford Biomedica PLC 5.25 GBp +0.60
Skyepharma PLC 321.50 GBp +5.25
Vernalis PLC 49.75 GBp +0.75
View Industry Companies
 

Industry Analysis

SAZ

Industry Average

Valuation SAZ Industry Range
Price/Earnings 11.3x
Price/Sales 0.7x
Price/Book 1.5x
Price/Cash Flow 11.2x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit www.stada.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.